[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE69924483D1 - Kombinationstherapie zur behandlung von tumoren - Google Patents

Kombinationstherapie zur behandlung von tumoren

Info

Publication number
DE69924483D1
DE69924483D1 DE69924483T DE69924483T DE69924483D1 DE 69924483 D1 DE69924483 D1 DE 69924483D1 DE 69924483 T DE69924483 T DE 69924483T DE 69924483 T DE69924483 T DE 69924483T DE 69924483 D1 DE69924483 D1 DE 69924483D1
Authority
DE
Germany
Prior art keywords
combination therapy
tumors
treatment
gastrin
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69924483T
Other languages
English (en)
Other versions
DE69924483T2 (de
Inventor
C Gevas
Stephen Grimes
L Karr
A Watson
Dov Michaeli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Receptor Biologix Inc
Original Assignee
Aphton Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aphton Corp filed Critical Aphton Corp
Application granted granted Critical
Publication of DE69924483D1 publication Critical patent/DE69924483D1/de
Publication of DE69924483T2 publication Critical patent/DE69924483T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69924483T 1998-05-15 1999-05-14 Kombinationstherapie zur behandlung von tumoren Expired - Lifetime DE69924483T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8568798P 1998-05-15 1998-05-15
US85687P 1998-05-15
PCT/US1999/010750 WO1999059628A2 (en) 1998-05-15 1999-05-14 Combination therapy for the treatment of tumors

Publications (2)

Publication Number Publication Date
DE69924483D1 true DE69924483D1 (de) 2005-05-04
DE69924483T2 DE69924483T2 (de) 2006-02-09

Family

ID=22193286

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69924483T Expired - Lifetime DE69924483T2 (de) 1998-05-15 1999-05-14 Kombinationstherapie zur behandlung von tumoren

Country Status (16)

Country Link
EP (1) EP1076561B1 (de)
JP (1) JP2002515457A (de)
KR (1) KR100699574B1 (de)
CN (1) CN1216605C (de)
AT (1) ATE291918T1 (de)
AU (1) AU745749B2 (de)
CA (1) CA2327439C (de)
DE (1) DE69924483T2 (de)
DK (1) DK1076561T3 (de)
ES (1) ES2237103T3 (de)
HK (1) HK1032360A1 (de)
HU (1) HUP0101947A3 (de)
PL (1) PL193109B1 (de)
PT (1) PT1076561E (de)
WO (1) WO1999059628A2 (de)
ZA (1) ZA200005962B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076499A2 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
JP2004536835A (ja) * 2001-07-09 2004-12-09 アフトン コーポレーション 肝臓、肺および食道の癌性ならびに前癌性状態の治療および防止
JP2005535663A (ja) * 2002-07-03 2005-11-24 アフトン コーポレーション リポソームワクチン
CN1781023A (zh) 2003-03-28 2006-05-31 埃弗顿有限公司 胃泌素激素免疫测定
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
CN101797382B (zh) * 2010-03-03 2013-11-20 戚胜美 抗人前胃液素多肽免疫组合物
US8674064B2 (en) 2010-03-03 2014-03-18 Onkologix Ltd Immunogenic compositions against human progastrin peptides
EA201100464A1 (ru) * 2011-04-06 2012-10-30 Ооо "Метамакс" (Ооо "Метамах") Фармацевтическая композиция для лечения гиперпролиферативных заболеваний и её применение
DK3071206T3 (da) 2013-11-22 2021-05-25 CL BioSciences LLC Gastrinantagonister (eg yf476, netazepid) til behandling og forebyggelse af osteoporose
KR20200015943A (ko) 2017-06-15 2020-02-13 캔설 어드밴스 아이엔씨 종양 및 암에 대한 체액성 및 세포 면역을 유도하기 위한 조성물 및 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341281C (en) * 1986-07-09 2001-08-07 Hubert J.P. Schoemaker Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen
DE69014137T2 (de) * 1989-01-24 1995-06-08 Aphton Corp., Woodland, Calif. Immunogenische Zusammensetzungen gegen Gastrin-Peptide.
US5468494A (en) * 1993-11-12 1995-11-21 Aphton Corp. Immunogenic compositions against human gastrin 17

Also Published As

Publication number Publication date
HK1032360A1 (en) 2001-07-20
AU745749B2 (en) 2002-03-28
ES2237103T3 (es) 2005-07-16
PL344414A1 (en) 2001-11-05
JP2002515457A (ja) 2002-05-28
ZA200005962B (en) 2002-01-24
DK1076561T3 (da) 2005-06-06
KR20010052355A (ko) 2001-06-25
WO1999059628A2 (en) 1999-11-25
PL193109B1 (pl) 2007-01-31
EP1076561B1 (de) 2005-03-30
ATE291918T1 (de) 2005-04-15
DE69924483T2 (de) 2006-02-09
KR100699574B1 (ko) 2007-03-23
HUP0101947A2 (hu) 2001-11-28
PT1076561E (pt) 2005-08-31
HUP0101947A3 (en) 2001-12-28
CN1303288A (zh) 2001-07-11
WO1999059628A3 (en) 2000-01-13
EP1076561A2 (de) 2001-02-21
CA2327439A1 (en) 1999-11-25
AU3904599A (en) 1999-12-06
CN1216605C (zh) 2005-08-31
CA2327439C (en) 2005-07-05

Similar Documents

Publication Publication Date Title
EA200000994A1 (ru) Применение кабэрголина при лечении синдрома усталых ног
ATE393831T1 (de) Zusammensetzung zur in vivo erzeugung von therapeutischen produkten
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
DE69733132D1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
ATE331534T1 (de) Anwendung von zielgerichtetem radium 223 für palliative und therapeutische behandlung von knochenkrebs
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
GR3034162T3 (en) Liposome-encapsulated taxol, its preparation and its use
DK85786D0 (da) Biologisk aktive fragmenter af human antihaemofilisk faktor og fremgangsmaade til fremstilling deraf
SE9404196D0 (sv) New antithrombotic formulation
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
GR3022321T3 (en) Use of il-4 to treat solid tumors
ATE232394T1 (de) Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
DE69310528D1 (de) Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft
ATE291918T1 (de) Kombinationstherapie zur behandlung von tumoren
DE69316013D1 (de) Verwendung von phosphinate zur behandlung der osteoporose
MX9701187A (es) Nuevas lactamas naftofusionadas n-substituidas.
DE69800859D1 (de) Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen
IL133172A0 (en) Diphosphonic acid salts for the treatment of osteoporosis
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69803298D1 (de) Verwendung des wachstumshormons in mitteln zur behandlung der insulinresistenz im herzen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: RECEPTOR BIOLOGIX, INC. (N.D.GES.D. STAATES DE, US